Lexicon Rises as Drug Limits Cancer Patients’ Diarrhea
This article is for subscribers only.
Lexicon Pharmaceuticals Inc. soared after reporting positive results in a late-stage trial treating a debilitating symptom for patients with a rare form of cancer.
Lexicon rose as much as 64 percent to $13.80, the biggest intraday increase in almost six years. The company said Monday that its drug reduced the frequency of bowel movements in a trial of 135 patients with carcinoid syndrome who weren’t getting adequate results from the standard treatment.